tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kristen Kluska, 303 are a BUY (91.82%), 27 are a HOLD (8.18%).
Analyst Kristen Kluska, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 36.95% that have a potential upside of 35.28% achieved within 113 days.
Kristen Kluska’s has documented 618 price targets and ratings displayed on 53 stocks. The coverage is on Healthcare, Industrials sectors.
Most recent stock forecast was given on CLDX, Celldex Therapeutics at 22-Sep-2026.
Analyst best performing recommendations are on QURE (UNIQURE NV).
The best stock recommendation documented was for QURE (UNIQURE NV) at 9/22/2025. The price target of $47 was fulfilled within 2 days with a profit of $33.17 (239.84%) receiving and performance score of 1199.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 20-Mar-2025
$57
$25.9 (83.28%)
$50
9 days ago
(23-Sep-2026)
2/6 (33.33%)
$25.88 (83.16%)
237
Buy Since 10-Sep-2021
$88
$56.9 (182.96%)
$78
9 days ago
(23-Sep-2026)
0/4 (0%)
$56.88 (182.78%)
Buy Since 21-Feb-2020
$72
$40.9 (131.51%)
$61
10 days ago
(22-Sep-2026)
4/22 (18.18%)
$38.49 (114.86%)
59
Buy Since 03-Jun-2014
$64
$32.9 (105.79%)
$42
10 days ago
(22-Sep-2026)
8/35 (22.86%)
$30.49 (90.99%)
145
Buy Since 08-May-2026
$53
$21.9 (70.42%)
$48
1 months 25 days ago
(07-Aug-2026)
2/6 (33.33%)
$11.29 (27.07%)
36
Which stock is Kristen Kluska most bullish on?
Which stock is Kristen Kluska most reserved on?
What Year was the first public recommendation made by Kristen Kluska?
